Topic

California

A collection of 516 issues

How to Get Uptravi (Selexipag) Covered by UnitedHealthcare in California: Complete Guide with Forms, Appeals, and Timelines

Answer Box: Getting Uptravi Covered by UnitedHealthcare in California UnitedHealthcare requires prior authorization for Uptravi (selexipag) and typically enforces step therapy requiring prior trials of other PAH medications. To get approval: 1) Submit PA through the UnitedHealthcare Provider Portal with complete WHO Group I PAH documentation and medication history, 2)
6 min read

How to Get Mepsevii (vestronidase alfa-vjbk) Covered by Aetna (CVS Health) in California: Prior Authorization Guide and Appeal Process

Answer Box: Getting Mepsevii Covered by Aetna (CVS Health) in California Mepsevii (vestronidase alfa-vjbk) requires prior authorization from Aetna with strict medical necessity criteria. Success requires: (1) confirmed MPS VII diagnosis via enzyme assay or genetic testing, (2) elevated urinary GAGs ≥2× normal, and (3) prescription by a metabolic specialist.
5 min read

How to Get Tavalisse (Fostamatinib) Covered by Aetna CVS Health in California: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Tavalisse Approved by Aetna CVS Health in California Aetna CVS Health requires prior authorization for Tavalisse (fostamatinib) with strict step therapy criteria including documented failure of corticosteroids, IVIG, and TPO receptor agonists. Your fastest path: Have your hematologist submit a complete PA request via the Aetna provider
6 min read

How to Get Vitrakvi (larotrectinib) Covered by Cigna in California: Complete Guide to Prior Authorization and Appeals

Answer Box: Quick Path to Coverage Cigna requires prior authorization for Vitrakvi (larotrectinib) in California, with approval typically within 5 business days when complete documentation is submitted. Your oncologist must provide NTRK fusion test results, treatment history, and medical necessity justification. If denied, California's Independent Medical Review (IMR)
6 min read